Skip to main content

Table 2 Predicted effectiveness of the screening programme per 100,000 neonates

From: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis

20 years horizon

Mean value

95% CI

Life years gained

1.0

0.7 – 1.4

DALY averted

3.7

2.9 – 4.5

70 years horizon

Mean value

95% CI

Life years gained

4.1

3.0 – 5.7

DALY averted

6.0

4.7 – 7.5